To show that the rate of first time stent re-vascularization (angioplasty/stent) and CABG is reduced by 32% and 40% essentially a NNT (number needed to treat) of 24 (Rx 24 candidates to save one the outcome) is nothing short of phenomenal, and do it with statin on board and baseline best medical therapy is even more impressive. If I had to choose between aspirin and Vascepa for a reduce-it patient no prizes for guessing which I would reach. The economics on reducing this percentage of first time PCI/stent and CABG procedures is mind-blowing--every insurance formulary in the USA should have this on board for REDUCE-IT like patients at present costs if they value their bottom line.
News 
Market Data 
Discover 
